Correction (DOI:10.1016/j.clpt.2005.06.005);Cytochrome P450 2C9 genotype: Impact on celecoxib safety and pharmacokinetics in a pediatric patient

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 3, 2005, Pages 309-310

  Stempak, Diana ^a   Bukaveckas, Bonny L ^b   Linder, Mark ^b   Koren, Gideon ^a   Baruchel, Sylvain ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CELECOXIB; CYTOCHROME P450 2C9;

ALLELE; ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE REPORT; CHILD; CLINICAL TRIAL; DRUG SAFETY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; LETTER; PRIORITY JOURNAL;

EID: 24344485994     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.10.002     Document Type: Erratum

References (4)

1. D. Stempak, J. Gammon, J. Klein, G. Koren, S. Baruchel Single-dose and steady-state pharmacokinetics of celecoxib in children Clin Pharmacol Ther 72 2002 490 497
2. D. Stempak, J. Gammon, J. Halton, M. Champagne, G. Koren, S. Baruchel Modulation of celecoxib pharmacokinetics by food in pediatric patients Clin Pharmacol Ther 77 2005 226 228
3. J. Kirchheiner, E. Stormer, C. Meisel, N. Steinbach, I. Roots, J. Brockmoller Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites Pharmacogenetics 13 2003 473 480
4. C. Tang, M. Shou, T.H. Rushmore, Q. Mei, P. Sandhu, E.J. Woolf In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9 correlation with CYP2C9 genotype and in-vivo pharmacokinetics Pharmacogenetics 11 2001 223 235